These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 8297795)
1. H-2/myc, E mu/myc, and c-myc transgenic mice: potent sources of early hematopoietic cell lines. Roland J; Morello D Cell Growth Differ; 1993 Nov; 4(11):891-900. PubMed ID: 8297795 [TBL] [Abstract][Full Text] [Related]
2. Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences. Sandlund JT; Neckers LM; Schneller HE; Woodruff LS; Magrath IT Cancer Res; 1993 Jan; 53(1):127-32. PubMed ID: 8416737 [TBL] [Abstract][Full Text] [Related]
3. E mu N- and E mu L-myc cooperate with E mu pim-1 to generate lymphoid tumors at high frequency in double-transgenic mice. Möröy T; Verbeek S; Ma A; Achacoso P; Berns A; Alt F Oncogene; 1991 Nov; 6(11):1941-8. PubMed ID: 1658705 [TBL] [Abstract][Full Text] [Related]
4. The 5' and 3' non-coding sequences of the c-myc gene, required in vitro for its post-transcriptional regulation, are dispensable in vivo. Morello D; Lavenu A; Pournin S; Babinet C Oncogene; 1993 Jul; 8(7):1921-9. PubMed ID: 8510935 [TBL] [Abstract][Full Text] [Related]
5. The cis-acting elements known to regulate c-myc expression ex vivo are not sufficient for correct transcription in vivo. Lavenu A; Pournin S; Babinet C; Morello D Oncogene; 1994 Feb; 9(2):527-36. PubMed ID: 8290263 [TBL] [Abstract][Full Text] [Related]
6. Retroviral infection accelerates T lymphomagenesis in E mu-N-ras transgenic mice by activating c-myc or N-myc. Haupt Y; Harris AW; Adams JM Oncogene; 1992 May; 7(5):981-6. PubMed ID: 1570158 [TBL] [Abstract][Full Text] [Related]
7. The transgenic window on lymphoid malignancy. Adams JM; Harris AW; Vaux DL; Alexander WS; Rosenbaum H; Klinken SP; Strasser A; Bath ML; McNeall J; Cory S Princess Takamatsu Symp; 1989; 20():297-309. PubMed ID: 2518688 [TBL] [Abstract][Full Text] [Related]
8. Increased transcription of the E mu-myc transgene and mRNA stabilisation produce only a modest elevation in Myc protein. Colley SM; Tilbrook PA; Klinken SP Oncogene; 1997 Jun; 14(22):2735-9. PubMed ID: 9178772 [TBL] [Abstract][Full Text] [Related]
9. Different regulation of class I gene expression in the adult mouse and during development. Drezen JM; Nouvel P; Babinet C; Morello D J Immunol; 1992 Jul; 149(2):429-37. PubMed ID: 1624790 [TBL] [Abstract][Full Text] [Related]
10. Hemopoietic neoplasms in lethally irradiated mice repopulated with bone marrow cells carrying the human c-myc oncogene: a repopulation assay. Hirabayashi Y; Inoue T; Suda Y; Aizawa S; Ikawa Y; Kanisawa M Exp Hematol; 1992 Feb; 20(2):167-72. PubMed ID: 1544384 [TBL] [Abstract][Full Text] [Related]
11. B-cell tumorigenesis in mice carrying a yeast artificial chromosome-based immunoglobulin heavy/c-myc translocus is independent of the heavy chain intron enhancer (Emu). Palomo C; Zou X; Nicholson IC; Bützler C; Brüggemann M Cancer Res; 1999 Nov; 59(21):5625-8. PubMed ID: 10554044 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of the translocated c-myc in Burkitt's lymphoma by a PNA complementary to the E mu enhancer. Cutrona G; Carpaneto EM; Ponzanelli A; Ulivi M; Millo E; Scarfì S; Roncella S; Benatti U; Boffa LC; Ferrarini M Cancer Res; 2003 Oct; 63(19):6144-8. PubMed ID: 14559793 [TBL] [Abstract][Full Text] [Related]
13. Antisense oligodeoxynucleoside methylphosphonate inhibition of mouse c-myc p65 protein expression in E mu-c-myc transgenic mice. Wickstrom E; Bacon TA; Wickstrom EL; Werking CM; Palmiter RD; Brinster RL; Sandgren EP Nucleic Acids Symp Ser; 1991; (24):151-4. PubMed ID: 1841270 [TBL] [Abstract][Full Text] [Related]
14. Dynamic regulation of c-Myc proto-oncogene expression during lymphocyte development revealed by a GFP-c-Myc knock-in mouse. Huang CY; Bredemeyer AL; Walker LM; Bassing CH; Sleckman BP Eur J Immunol; 2008 Feb; 38(2):342-9. PubMed ID: 18196519 [TBL] [Abstract][Full Text] [Related]
15. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Strasser A; Harris AW; Bath ML; Cory S Nature; 1990 Nov; 348(6299):331-3. PubMed ID: 2250704 [TBL] [Abstract][Full Text] [Related]
16. Growth of E mu-myc transgenic B-lymphoid cells in vitro and their evolution toward autonomy. Langdon WY; Harris AW; Cory S Oncogene Res; 1988; 3(3):271-9. PubMed ID: 3144697 [TBL] [Abstract][Full Text] [Related]
17. Lymphoproliferative syndrome associated with c-myc expression driven by a class I gene promoter in transgenic mice. Morello D; Lavenu A; Bandeira A; Portnoi D; Gaillard J; Babinet C Oncogene Res; 1989; 4(2):111-25. PubMed ID: 2654814 [TBL] [Abstract][Full Text] [Related]
18. Transgenic N-myc mouse model for indolent B cell lymphoma: tumor characterization and analysis of genetic alterations in spontaneous and retrovirally accelerated tumors. Sheppard RD; Samant SA; Rosenberg M; Silver LM; Cole MD Oncogene; 1998 Oct; 17(16):2073-85. PubMed ID: 9798678 [TBL] [Abstract][Full Text] [Related]
19. Development and characterization of v-myc/v-raf-transformed murine fetal thymocyte cell lines. Taubenberger JK; Reid AH; Izon D; Boehme SA Cell Immunol; 1996 Jul; 171(1):41-7. PubMed ID: 8754860 [TBL] [Abstract][Full Text] [Related]
20. Variable IgH chain enhancer activity in Burkitt's lymphomas suggests an additional, direct mechanism of c-myc deregulation. Jain VK; Judde JG; Max EE; Magrath IT J Immunol; 1993 Jun; 150(12):5418-28. PubMed ID: 8515068 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]